Prolocor

Executive Summary

Prolocor is a San Diego-based diagnostics company founded in 2019, developing a novel blood test that quantifies the FcγRIIa receptor on platelet surfaces. This receptor plays a key role in thrombosis and inflammation, offering a more precise tool for assessing cardiovascular disease (CVD) risk compared to traditional lipid-based tests. By measuring receptor density, Prolocor aims to guide individualized therapy, potentially improving outcomes in high-risk patients. The test addresses an unmet need in precision cardiology, where current risk stratification often fails to capture residual risk. The company is in the early development stage, focusing on clinical validation studies to demonstrate the test's predictive value. Given the large addressable market for CVD diagnostics, Prolocor's technology could be a critical adjunct to existing risk scores. Near-term catalysts include the initiation or results of a pivotal clinical study, securing a strategic partnership with a major diagnostics or pharmaceutical company, and obtaining FDA breakthrough device designation to accelerate regulatory review. The company's innovative approach and focus on a validated biomarker position it well, but it remains pre-revenue with limited public data.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical validation study70% success
• Q4 2026FDA breakthrough device designation60% success
• TBDPartnership with major diagnostics or pharma company50% success